Inovio Pharmaceuticals
126 hedge funds and large institutions have $135M invested in Inovio Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 19 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 3.89% → 3.89% (-0%)
1% less funds holding
Funds holding: 127 → 126 (-1)
6% less call options, than puts
Call options by funds: $299K | Put options by funds: $318K
21% less capital invested
Capital invested by funds: $171M → $135M (-$36.2M)
Top Buyers
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$8.11M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.98M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.18M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.16M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.48M |
INO Hedge Fund Activity: Q2 2019 in Review
126 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2019, worth a combined $135M — down 21% from $171M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new INO positions and 19 closed out — a net gain of 2 holders — while 37 added to existing stakes and 27 trimmed.
The largest buyer was Sumitomo Mitsui Trust Group, adding an estimated $5.61M. The largest seller was State Street, cutting an estimated $8.11M.
- 126 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2019, down from 127 in Q1 2019.
- Funds reported $135M of Inovio Pharmaceuticals stock for Q2 2019, down 21% quarter-over-quarter.
- 21 funds opened new Inovio Pharmaceuticals positions in Q2 2019 and 19 closed out, a net change of +2 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2019 was Sumitomo Mitsui Trust Group, an estimated $5.61M added.
- The largest Inovio Pharmaceuticals seller in Q2 2019 was State Street, an estimated $8.11M sold.
Based on aggregated 13F filings for Q2 2019.